PRCS Message Board - Msg: 15928874

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: hmpa who wrote (32)	6/12/2001 7:46:53 AM
From: dalroi	Read Replies (2) of 78

well if it was avalon then they did it again NEW YORK (Reuters) - Amgen Inc. (NasdaqNM:AMGN - news) and Praecis Pharmaceuticals Inc. (NasdaqNM:PRCS - news) on Tuesday said they had received a letter from U.S. regulators stating that their New Drug Application for a prostate cancer treatment is ``inadequate for approval.'' The two biotech companies said in a statement that they plan to meet with the U.S. Food and Drug Administration (news - web sites) ``in an effort to clarify the various deficiencies cited in the FDA's letter, and to discuss what further steps need to be taken before the application may be approved.'' Amgen and Praecis submitted a New Drug Application for their experimental drug, called Plenaxis, for the treatment of hormonally responsive prostate cancer. The NDA was submitted in December

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next